Incretin-based drugs and renoprotection—is hyperfiltration key?
نویسندگان
چکیده
منابع مشابه
Incretin-based drugs and the risk of congestive heart failure.
OBJECTIVE To determine whether the use of incretin-based drugs, including GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, is associated with an increased risk of congestive heart failure (CHF) among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS The U.K. Clinical Practice Research Datalink, linked to the Hospital Episode Statistics database, was used to conduct a cohort study...
متن کاملPancreatic safety of incretin-based drugs--FDA and EMA assessment.
n engl j med 370;9 nejm.org february 27, 2014 794 likely that such efficacy will be shown until the vaccines are licensed and postmarketing surveillance commences. Recent evidence suggests that EV71 vaccines do not provide cross-protection against all circulating genetic lineages of EV71 or against coxsackievirus A16.5 Thus, the Chinese C4A-based vaccines may not generate protective immunity ag...
متن کاملIncretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.
Over the past few years, substantial clinical data have been presented showing that incretin-based therapies are effective glucose-lowering agents. Specifically, glucagon-like peptide 1 receptor agonists demonstrate an efficacy comparable to insulin treatment with minimal hypoglycemia and have favorable effects on body weight. Thus, many of the unmet clinical needs noted from prior therapies ar...
متن کاملIncretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
OBJECTIVES To determine whether the use of incretin based drugs, compared with sulfonylureas, is associated with an increased risk of acute pancreatitis. DESIGN Population based cohort study. SETTING 680 general practices in the United Kingdom contributing to the Clinical Practice Research Datalink. PARTICIPANTS From 1 January 2007 to 31 March 2012, 20 748 new users of incretin based drug...
متن کاملIncretin-based therapies
Incretin-based therapies have established a foothold in the diabetes armamentarium through the introduction of oral dipeptidyl peptidase-4 inhibitors and the injectable class, the glucagon-like peptide-1 receptor agonists. In 2009, the American Diabetes Association and European Association for the Study of Diabetes authored a revised consensus algorithm for the initiation and adjustment of ther...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International
سال: 2015
ISSN: 0085-2538
DOI: 10.1038/ki.2014.398